A new trading day began on Friday, with Replimune Group Inc (NASDAQ: REPL) stock price down -7.46% from the previous day of trading, before settling in for the closing price of $6.97. REPL’s price has ranged from $5.89 to $24.81 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -2.04%. With a float of $44.47 million, this company’s outstanding shares have now reached $56.68 million.
Let’s look at the performance matrix of the company that is accounted for 284 employees.
Replimune Group Inc (REPL) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Replimune Group Inc is 27.56%, while institutional ownership is 92.61%. The most recent insider transaction that took place on Nov 16 ’23, was worth 79,858. In this transaction Chief Medical Officer of this company sold 7,313 shares at a rate of $10.92, taking the stock ownership to the 112,714 shares. Before that another transaction happened on Nov 16 ’23, when Company’s Chief Commercial Officer sold 5,255 for $10.92, making the entire transaction worth $57,385. This insider now owns 72,245 shares in total.
Replimune Group Inc (REPL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 157.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.04% per share during the next fiscal year.
Replimune Group Inc (NASDAQ: REPL) Trading Performance Indicators
Here are Replimune Group Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 12.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.28, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -2.83 in one year’s time.
Technical Analysis of Replimune Group Inc (REPL)
Replimune Group Inc (NASDAQ: REPL) saw its 5-day average volume 0.9 million, a negative change from its year-to-date volume of 1.35 million. As of the previous 9 days, the stock’s Stochastic %D was 31.39%. Additionally, its Average True Range was 0.44.
During the past 100 days, Replimune Group Inc’s (REPL) raw stochastic average was set at 8.62%, which indicates a significant decrease from 8.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.97% in the past 14 days, which was lower than the 114.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.93, while its 200-day Moving Average is $12.66. Nevertheless, the first resistance level for the watch stands at $6.90 in the near term. At $7.36, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.64. If the price goes on to break the first support level at $6.16, it is likely to go to the next support level at $5.88. Assuming the price breaks the second support level, the third support level stands at $5.42.
Replimune Group Inc (NASDAQ: REPL) Key Stats
With a market capitalization of 395.97 million, the company has a total of 61,388K Shares Outstanding. Currently, annual sales are 0 K while annual income is -174,280 K. The company’s previous quarter sales were 0 K while its latest quarter income was -51,120 K.
